It Was Shkreli's Show, But Pharma Was On Trial
This article was originally published in Scrip
The House Oversight and Government Reform Committee hearing on drug prices was the hottest spot in a very damp and cold Washington on Feb. 4 and former Turing Pharmaceutical Inc. CEO Martin Shkreli gave lawmakers and the overflow-crowd in attendance what they were anticipating: Several big smirky smiles, a lot of eye rolling and a refusal to testify – citing his "Act of Production Privilege" under the Fifth Amendment to the US Constitution at the advice of his counsel.
You may also be interested in...
Mylan’s discussion of how the drug supply chain absorbs pricing for EpiPen raised more questions than it answered during a House Oversight Committee hearing